Table 2 Treatment effects
Streptozocin/5-FU | PRRT | Everolimus | |||||||
|---|---|---|---|---|---|---|---|---|---|
OR n = 22 | SD n = 10 | p-value | OR n = 39 | SD n = 17 | p-value | OR n = 12 | SD n = 40 | p-value | |
Age years, median mean) | 63 (63) | 65 (65) | 1.0 | 62 (62) | 65 | 0,2 | 65 (65) | 67 (66) | 0,9 |
Sex, female (%) | 10 (83) | 2 (17) | 0,2 | 20 (77) | 6 (23) | 0,2 | 2 (17) | 19 (48) | 0,06 |
Ongoing SSA treatment (%) | 3 (14) | 0 | 0,5 | 21 (54) | 10 (59) | 0,7 | 7 (58) | 25 (63) | 0,8 |
Prior treatments Median (mean) | 0 (0,6) | 0 (0,6) | 1,0 | 2 (1,8) | 2 (2,2) | 0,1 | 2,5 (2,4) | 3 (2,7) | 0,7 |
Ki67% Median (IQR) | |||||||||
Total group | 10 (10–13) | 10 (3–13) | 0,2 | 7 (3,5–10) | 6 (1–10) | 0,4 | 9 (3,5-11,5) | 9 (5–12) | 0,7 |
Pancreas | 10 (8–13) | 10 (10–14) | 0,7 | 7 (4–12,5) | 10 (5,5–10) | 1,0 | 8 (5–13) | 10 (8,5-12,5) | 0,5 |
Small intestinal | – | – | – | 6 (2,5-11,5) | 3 (1–8,5) | 0,4 | 6 (1,5–10) | 7 (3–11,5) | 0,4 |
Stage No. patients (%) | |||||||||
Regional | 1 (5) | 1 (10) | 0,5 | 1 (3) | 0 | 0,5 | 1 (8) | 3 (8) | 0,9 |
Distant | 21 (95) | 9 (90) | 38 (97) | 17 (100) | 11 (92) | 37 (92) | |||